Endothelial Dysfunction Market Report 2026

The endothelial dysfunction market size has grown strongly in recent years. It will grow from $2.9 billion in 2025 to $3.07 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, rising incidence of metabolic disorders, expansion of preventive healthcare screening, availability of endothelial biomarkers, growing clinical focus on vascular health.

The endothelial dysfunction market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for remote patient monitoring, expansion of AI-driven cardiovascular diagnostics, growing investments in preventive cardiology, increasing focus on personalized treatment pathways. Major trends in the forecast period include increasing use of advanced endothelial function diagnostics, rising adoption of biomarker-based screening, growing integration of digital health monitoring tools, expansion of personalized vascular treatment approaches, enhanced focus on early cardiovascular risk detection.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the endothelial dysfunction market in the coming years. Cardiovascular diseases encompass a broad group of disorders affecting the heart and blood vessels, and their prevalence continues to rise globally due to demographic changes and lifestyle-related health risks. The increasing burden of cardiovascular diseases is driven primarily by population aging, urbanization, unhealthy diets, physical inactivity, and prolonged exposure to metabolic and vascular stress, all of which contribute to progressive endothelial damage over time. Endothelial dysfunction plays a pivotal role in the onset and progression of cardiovascular diseases, as impaired endothelial regulation leads to vascular inflammation, reduced nitric oxide availability, abnormal vasodilation, and atherosclerotic plaque development. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4% from 224.4 per 100,000 in 2023. Therefore, the rising prevalence and burden of cardiovascular diseases is driving the growth of the endothelial dysfunction market.

The rising demand for precision medicine is anticipated to drive the growth of the endothelial dysfunction market in the coming years. Precision medicine is a healthcare approach that customizes prevention and treatment strategies for individual patients based on their genetic profile, environment, and lifestyle. The growing emphasis on precision medicine is fueled by improved treatment outcomes, as therapies tailored to a patient’s genetic and biological characteristics lead to better efficacy and reduced risk of adverse effects. The increasing demand for precision medicine supports endothelial dysfunction management by utilizing genetic, molecular, and biomarker profiling to pinpoint the specific biological mechanisms responsible for endothelial damage in each patient, enabling clinicians to choose or develop targeted therapies that enhance therapeutic effectiveness while minimizing unnecessary or ineffective interventions. For example, in February 2025, according to NHS England, a UK-based public healthcare organization, in 2024, the NHS Genomic Medicine Service conducted over 810,000 genomic tests for patients across the life course in England, representing an 8% increase compared to 2023 and reflecting a continued year-on-year growth since the service was established. Therefore, the rising demand for precision medicine is driving the growth of the endothelial dysfunction market.

In March 2025, Alcon, a Switzerland-based provider of ophthalmic surgical devices, vision care products, and eye care solutions, acquired Aurion Biotech for an undisclosed amount. Through this acquisition, Alcon seeks to strengthen its ophthalmology portfolio by expanding into regenerative and cell-based therapies, particularly for corneal diseases, while enhancing its long-term innovation pipeline in eye care. Aurion Biotech is a US-based company specializing in cell therapies for corneal endothelial dysfunction, including treatments for conditions such as corneal edema and bullous keratopathy.

Major companies operating in the endothelial dysfunction market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc., Bayer Aktiengesellschaft, Sanofi S.A., Novartis Aktiengesellschaft, Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Siemens Healthineers AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Boston Scientific Corporation, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Biogen Inc., ChugAI Pharmaceutical Co. Ltd., ZOLL Medical Corporation, OrbusNeich Medical Group Holdings Limited, Stealth Peptides Inc., Perimed AB, and Glucox Biotech AB.

Tariffs are impacting the endothelial dysfunction market by increasing costs of imported diagnostic instruments, assay reagents, biomarker kits, imaging devices, and digital monitoring hardware. Healthcare providers in North America and Europe are most affected due to reliance on imported medical technologies, while Asia-Pacific faces higher costs in diagnostic equipment procurement. These tariffs are increasing testing costs and slowing adoption in routine screenings. However, they are also supporting local manufacturing of diagnostic kits, regional innovation in digital health platforms, and domestic development of vascular assessment technologies.

The endothelial dysfunction market research report is one of a series of new reports that provides endothelial dysfunction market statistics, including endothelial dysfunction industry global market size, regional shares, competitors with a endothelial dysfunction market share, detailed endothelial dysfunction market segments, market trends and opportunities, and any further data you may need to thrive in the endothelial dysfunction industry. This endothelial dysfunction market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endothelial dysfunction is a pathological condition in which the endothelial layer (the inner lining of blood vessels) fails to regulate vascular tone, blood flow, and homeostasis effectively. It is linked with reduced nitric oxide production, inflammation, and oxidative stress, and plays a key role in the onset of cardiovascular diseases, diabetes, hypertension, and other vascular disorders.

The core product types of endothelial dysfunction include diagnostics, therapeutics, digital health solutions, pharmacological agents, non-pharmacological interventions, and biological therapies. Diagnostics refer to tools and tests used to identify and monitor endothelial dysfunction in patients. These solutions leverage technologies such as biotechnology, nanotechnology, genomics, and proteomics. The applications include cardiovascular risk, metabolic syndrome, chronic kidney disease, and other applications, and the end users are hospitals, diagnostic laboratories, specialty clinics, and primary care providers.

The endothelial dysfunction market consists of revenues earned by entities by providing services such as diagnostic testing and screening, biomarker analysis, clinical assessments of vascular function, personalized treatment planning, patient monitoring services, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The endothelial dysfunction market also includes sales of diagnostic kits, biomarkers, assay reagents, imaging devices, and vascular function monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.